ARCHIVES

DCT Board Okays Contract Recompetitions, But Litton Bionetics May Be Barred From Two Supporting Gall’s Lab, Plus FCRF Program

This article is from The Cancer Letter archive.

Vol. 11 No. 42 | November 1, 1985

Download PDF Visit The Full Archive

Related Articles

Lederle Scientists Report Powerful New Anticancer Agent

July 31, 1987

In Multi-Site Phase I Studies, No Investigator Sees All Toxicities

March 26, 2010

In Brief: Mary-Claire King Named Disney Professor By Cancer Society; Date Corrected In Article

July 1, 1994

NCI’s $65 Million to NTP Will Be Controversial, Untouchable; Spectre Of Another Backlog Looms

February 8, 1980

UICC Receives 1300 Abstracts For Congress In Oslo, Norway.

February 22, 2002

RFPs Go Out To Cooperative Groups for Community Programs

April 9, 1976